Startups
Kesmalea Therapeutics
Kesmalea Therapeutics Limited is a UK preclinical drug-discovery company founded by medicinal chemist Harry Finch in2020 (company12961631, incorporated20October2020). Its SELFTAC platform uses reversible linkers to let smaller components assemble into targeted protein degraders, addressing the drug-like properties and central-nervous-system delivery limits of larger bifunctional molecules. Research targets oncology and CNS disease; brain penetration is a development objective, not a claim of clinical efficacy or regulatory approval. Robert Johnson is CEO, with published scientific, finance and discovery leaders and an independently verified board. Syncona and Oxford Science Enterprises backed its2022 SeriesA. Primary historical Syncona reporting describes GBP20M/GBP16Mcommitment, while the current issuer and Syncona page report GBP25M/GBP20Mcommitment for2022; the unresolved allocation is source-qualified rather than summed as multiple cash raises. Syncona separately reports GBP5M additional financing in2023 and a GBP4M commitment. Commitment sizes, shareholding and carrying values are distinguished from verified paid investor tickets. The company describes an internal pipeline and potential collaborations; no unsupported AI focus is asserted.
Founded 2020
Team
Claire WalsheSenior Vice President, Early Research and Development |
Clive DixChairman |
 Craig FoxNon-Executive Director |
Harry FinchChief Scientific Officer; Founder Director |
Justin BowerVice President, Discovery and Technology Development |
Mark FoxFinance Director |
 Raghd RostomNon-Executive Director |
Robert JohnsonDirector · Chief Executive Officer |
 Stephen MolumbyNon-Executive Director |
Tim ClacksonNon-Executive Director |